ReviewDer Internist2009
[Liver transplantation: indications and results].
Review in Der Internist, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 32 citations in OpenAlex.
- Practice guidance for the use of terlipressin for liver cirrhosis-related complications.Therapeutic advances in gastroenterology · 2022Article
- Hepatic encephalopathy before and neurological complications after liver transplantation have no impact on the employment status 1 year after transplantation.World journal of hepatology · 2017Article
- [Hepatic steatosis : Differential diagnostics and current aspects].Der Internist · 2016Review
- HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations?Visceral medicine · 2016Review
- [Allocation systems in transplantation medicine: Advantages and disadvantages].Der Internist · 2016Article
- The current state and future prospects of chronic hepatitis C virus infection treatment.Current infectious disease reports · 2014Article
- [Patient selection and indications for liver transplantation].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2013Review
- [Treatment of autoimmune liver diseases. Autoimmune hepatitis and primary sclerosing cholangitis].Der Internist · 2011Article
- [Intensive therapy after solid organ transplantation].Der Anaesthesist · 2010Article
- [Pulmonary complications of liver cirrhosis: hepatopulmonary syndrome, portopulmonary hypertension and hepatic hydrothorax].Der Internist · 2010Review
- [Diagnostics and therapy of hepatitis].Der Internist · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After around 64,000 transplantations in Europe since 1988 liver transplantation has emerged as a standard treatment option for otherwise incurable chronic liver diseases. Cirrhosis of different etiologies represents the most frequent transplant indication. Overall survival in this group amounts to 72% after 5 years, and 62% after 10 years. In Germany, the main indications include alcoholic liver cirrhosis, tumors with increasing numbers in recent years, as well as viral diseases leading to cirrhosis. Since December 2006 the priority for liver transplantation is determined by the model for end stage liver disease (MELD) and not by the length of waiting time. MELD is a statistical model based on serum creatinine, serum bilirubin and coagulation, which describes the probability of 3-month mortality of a potential transplant candidate. Not all liver diseases are adequately represented by MELD necessitating the additional use of a defined number of standard exceptions that have been last updated in 2008. As a consequence of these developments indications, selection of recipients and the management of the waiting list have seen profound change.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.